Isodiol International Inc. (CSE:ISOL, OTC:LAGBF, FSE:LBGA.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has received approval from the Brazilian Health Regulatory Agency (ANVISA) This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists. This is now the Company’s second product to receive medical approval by the ANVISA.

“We have been working towards additional products for the Brazilian medical community and for the last several months, so to have our second product medically approved by ANVISA is a tremendous breakthrough for the company,” said CEO of Isodiol, Marcos Agramont.  “We have been working with neurologists and medical practitioners to offer an alternative delivery method of cannabidiol and Isodiolex is the perfect solution for this.  Overall, we will continue to be proactive in increasing our global footprint, especially where cannabinol is medically approved, affording us the opportunity to truly show how cannabinol is beneficial for the human body.”


Additional information around Isodiolex will be provided in the coming weeks.

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com

Forward-Looking Information:This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

Click here to connect with Isodiol International Inc. (CSE:ISOL, OTC:LAGBF, FSE:LBGA.F) to receive an Investors Presentation.

Source: markets.businessinsider.com

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less

For the purposes of the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, World High Life announces that the Company has 230,119,819 ordinary shares of 1p each in issue (“Ordinary Shares”), each share carrying the right to one vote. The figure of 230,119,819 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules

The Directors of the Company accept responsibility for the contents of this announcement.

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) announces that it has granted an aggregate of 400,000 options at an exercise price of CDN$1.00, exercisable for a period of five years, to directors and officers of the Company. The stock options are being granted pursuant to the terms of the Company’s stock option plan, and are subject to regulatory approval.

About TransCanna Holdings Inc.

Keep reading... Show less

Donation will benefit veteran-focused organizations and nonprofits, including all TruVet Program partners

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a United States -based leading medical cannabis company, announced today a donation for all TruVet Program partners year-to-date in honor of Veterans Day. A total of $15,000 representing a portion of the November proceeds from the Company’s limited-edition Freedom Pre-Roll product, will be shared among program partners, which are veteran-focused organizations andor nonprofits.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannibas, Inc. (“Aurora” or the “Company”) (NYSE:ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.comacb

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less